DexCom, Inc. vs Moody's Corporation — how do they compare? DexCom, Inc. trades at $89.97 (market cap $33.79B), while Moody's Corporation trades at $477.76 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 2.4× DexCom, Inc.'s market cap, and Moody's Corporation pays a 0.86% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MCO | |
|---|---|---|
Market Cap | $33.79B | $82.52B |
Sector | Health | Financials |
52-Week High | $89.53 | $539.61 |
52-Week Low | $54.84 | $412.23 |
Enterprise Value | $33.24B | $88.54B |
Dividend Yield | — | 0.86% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Moody's Corporation (MCO) trades at $478.14, showing modest daily gains of 0.08%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust profitability metrics, including 34.25% net income margin and 80.15% ROE. Recent Q2 2026 results exceeded expectations with $4.68 EPS versus $4.26 expected, driven by strong analytics demand and debt issuance activity. Technical indicators remain neutral with support at $475 and resistance at $481.
MCO presents a compelling growth story with premium valuation justified by exceptional profitability and market leadership. The primary investment opportunity lies in sustained analytics growth and credit rating dominance, while risks include valuation sensitivity and potential debt market volatility. Analyst consensus remains bullish with $561.88 price target representing 17.5% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →